Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 74

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 9B
Chunk 74
---
 to warrants to purchase shares of Common Stock held by the McCollum Living Trust as an equityholder of LENZ OpCo, (iv) 16,633 shares of common stock purchased by the McCollum Living Trust in the March 2024 PIPE Financing, (v) 31,332 purchased by the McCollum Living Trust in the open market, and (vi) 9,750 shares of Common Stock subject to options held by Mr. McCollum exercisable within 60 days of March 12, 2025. Mr. McCollum is a trustee of the McCollum Living Trust and as such has voting and investment control over the shares held by the McCollum Living Trust.

(12)Consists of shares of Common Stock subject to options held by Dr. Scheiner exercisable within 60 days of March 12, 2025. Dr. Scheiner is employed as a principal at RA Capital Management, L.P. Dr. Scheiner does not have voting or dispositive control over the shares held by the entities affiliated with RA Capital Management referenced in footnote 3 above.

(13)Consists of shares of Common Stock subject to options held by Ms. Thunen exercisable within 60 days of March 12, 2025.

(14)Consists of shares of Common Stock subject to options held by Mr. George exercisable within 60 days of March 12, 2025.

(15)Consists of shares of Common Stock subject to options held by Ms. Drapkin exercisable within 60 days of March 12, 2025.

(16)Consists of (i) 775,919 shares of Common Stock beneficially owned by our executive officers and directors, (ii) 1,093,752 shares of Common Stock subject to options held our executive officers and directors and exercisable within 60 days of March 12, 2025, and (iii) 6,575 shares of Common Stock subject to warrants beneficially owned by our executive officers and directors.

Please see the sections titled “Executive Compensation” and “Certain Relationships and Related Transactions, and Director Independence” appearing elsewhere in this Annual Report on Form 10-K for information regarding material relationships with our principal securityholders within the past two years.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Described below are any transactions occurring since January 1, 2023 and any currently proposed transactions to which we or either of Graphite